Log in to save to my catalogue

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1900125748

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

In a randomized trial involving patients with high-risk vascular disease, the cholesteryl ester transfer protein inhibitor evacetrapib had favorable effects on established lipid biomarkers but was not associated with a lower rate of cardiovascular events than placebo.
Pharmacologic reduction of the low-density lipoprotein (LDL) cholesterol level...

Alternative Titles

Full title

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1900125748

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1900125748

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1609581

How to access this item